Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Director departure
Inv. presentation
Quarterly results
Appointed director
CC transcript
OSI PHARMACEUTICALS INC (OSIP) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/09/2010 8-K Quarterly results
05/17/2010 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Other Events, Financial Sta...
Docs: "Agreement and Plan of Merger, among OSI Pharmaceuticals, Inc., Astellas Pharma Inc., Astellas US Holding, Inc. and Ruby Acquisition, Inc",
"Amendment No. 1 to the Rights Agreement, by and among OSI Pharmaceuticals, Inc. and The Bank of New York Mellon",
"Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. Companies enter into definitive merger agreement to combine to create a world- class oncology platform OSI Stockholders to receive $57.50 per share in cash Tokyo, Japan, and Melville, N.Y. - May 16, 2010 - Astellas Pharma Inc. , a global pharmaceutical company, and OSI Pharmaceuticals, Inc. , a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, today announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI. Under the terms of the merger agreement, Astellas will increase its offer price to $57.50 per share, which represents a premium of 55% to the closing..."
04/22/2010 8-K Quarterly results
Docs: "OSI Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results - Total Revenues Increased 14% Year over Year to $107 Million -",
"Script for OSI's First Quarter 2010 Earnings Conference Call held on April 22, 2010",
"FDA APPROVES TARCEVA AS A MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER"
04/15/2010 8-K Form 8-K - Current report
04/06/2010 8-K Amended existing or entered into new employment agreement with an officer
Docs: "OSI Change in Control Severance Plan, adopted by the OSI Board upon recommendation of the Compensation Committee of OSI Board on April 2, 2010",
"Prosidion Limited and OSI Pharmaceuticals (UK) Limited Change in Control Severance Plan, adopted by the OSI Board upon recommendation of the Compensation Committee of OSI Board on April 2, 2010",
"Amendment to Employment Agreement, by and between OSI Pharmaceuticals, Inc. and Dr. Jonathan Rachman",
"Employment Letter Agreement, by and between OSI Pharmaceuticals, Inc. and Dr. David Epstein",
"Amendment to Employment Letter Agreement, by and between OSI Pharmaceuticals, Inc. and Dr. David Epstein",
"Employment Letter Agreement, by and between OSI Pharmaceuticals, Inc. and Dr. Angela Davies",
"Amendment to Employment Letter Agreement, by and between OSI Pharmaceuticals, Inc. and Dr. Angela Davies",
"OSI Pharmaceuticals Announces Conversion Period for Convertible Notes",
"Conversion Notice for 2.0% Convertible Senior Subordinated Notes due 2025 of OSI Pharmaceutials, Inc."
03/24/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVAâ RECEIVED A POSITIVE OPINION FROM HEALTH AUTHORITIES IN THE EUROPEAN UNION FOR FIRST-LINE MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER",
"OSI PHARMACEUTICALS ANNOUNCES DETAILS OF REDEMPTION OF 3.25% CONVERTIBLE SENIOR SUBORDINATED NOTES"
03/01/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "OSI Pharmaceuticals Confirms Receipt of Unsolicited Proposal From Astellas Pharma - Advises Stockholders to Take No Action at this Time -"
02/24/2010 8-K/A Form 8-K - Current report [amend]
01/19/2010 8-K Form 8-K - Current report
01/12/2010 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "OSI Pharmaceuticals, Inc. Announces Fourth Quarter and 2009 Full Year Tarceva Sales at JP Morgan Healthcare Conference - Fourth Quarter U.S. Tarceva Sales Increased 17% on Prior Year to $137 Million – - Total Global Tarceva Sales for 2009 Top $1.2 Billion - MELVILLE, NEW YORK – January 12, 2010 – OSI Pharmaceuticals, Inc. will present fourth quarter and year end Tarceva® sales today during the Company’s presentation at the 28th Annual JP Morgan Healthcare Conference in San Francisco, CA. For the three months ended December 31, 2009, Tarceva U.S. net sales, as communicated to the Company by its collaborator Roche, were approximately $137 million. U.S. sales increased approximately $20 million over the same period last year and were up approximately $19 million over third quarter sales of ap..."
01/08/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA ADVISORY COMMITTEE RECOMMENDS AGAINST APPROVING TARCEVA FOR FIRST-LINE MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER",
"OSI Pharmaceuticals Updates Preliminary Revenue & Re-affirms Adjusted Earnings Growth Rate Guidance for 2010 - Mid-teen revenue growth for 2010 - - Adjusted earnings per share growth of 10% or more for 2010 - - OSI repurchased $79.5 million of 2023 & 2038 convertible bonds during December 2009 -",
"U.S. Patent and Trademark Office Grants Reissued Patent Replacing OSI Pharmaceuticals’ Tarceva® Composition of Matter Patent MELVILLE, NEW YORK – December 29, 2009 –"
12/04/2009 8-K Investor presentation
Docs: "Slides from December 3, 2009 R&D Analyst Day presentation"
10/21/2009 8-K Form 8-K - Current report
10/15/2009 8-K Other Events
07/24/2009 8-K/A Form 8-K - Current report [amend]
07/22/2009 8-K Quarterly results
Docs: "OSI Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results - Tarceva Global Net Sales of $290 million -",
"NEW DATA FROM PHASE III SATURN STUDY SHOWED TARCEVA IMPROVED OVERALL SURVIVAL WHEN USED IMMEDIATELY AFTER INITIAL CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SMALL CELL LUNG CANCER",
"OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration"
07/09/2009 8-K Form 8-K -- Current report
06/19/2009 8-K Other Events
06/03/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar ® and Tarceva ® in Patients with Liver Cancer",
"DATA FROM THE PHASE III ATLAS STUDY SHOW TARCEVA IN COMBINATION WITH AVASTIN AS FIRST-LINE MAINTENANCE THERAPY IMPROVED PROGRESSION-FREE SURVIVAL IN ADVANCED LUNG CANCER"
05/19/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "OSI PHARMACEUTICALS PROVIDES UPDATE ON DIABETES AND OBESITY CLINICAL PROGRAMS",
"DATA FROM THE PHASE III SATURN STUDY SHOW TARCEVA IMPROVED PROGRESSION-FREE SURVIVAL WHEN USED AS A FIRST- LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL",
"OSI PHARMACEUTICALS PROVIDES UPDATE ON OSI-906 DATA BEING PRESENTED ON MAY 30 TH AT THE UPCOMING ANNUAL MEETING OF"
04/29/2009 8-K Form 8-K -- Current report
04/24/2009 8-K Other Events
04/16/2009 8-K Form 8-K -- Current report
03/24/2009 8-K Form 8-K -- Current report
03/04/2009 8-K Form 8-K -- Current report
02/19/2009 8-K Quarterly results
Docs: "OSI Pharmaceuticals, Inc. Announces Year End 2008 Financial Results - Reports Non-GAAP Earnings of $2.14 Per Share from Continuing Operations, Excluding $337 Million Non-Cash Gain - - GAAP Earnings from Continuing Operations are $7.19 Per Share Inclusive of Non-Cash Gain - - Total Revenues of $379 Million Up 11% Over 2007 -"
02/12/2009 8-K Form 8-K -- Current report
02/04/2009 8-K Form 8-K -- Current report
01/16/2009 8-K Form 8-K -- Current report
12/18/2008 8-K Form 8-K -- Current report
12/16/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "Employment Agreement, by and between OSI Pharmaceuticals, Inc. and Pierre Legault",
"OSI Pharmaceuticals Announces the Appointment of Mr. Pierre Legault as Executive Vice President and Chief Financial Officer"
12/04/2008 8-K Investor presentation
Docs: "Slides from December 4, 2008 R&D Analyst Day presentation",
"TARCEVA ® ENDORSED BY THE U.K.'s NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE FOR USE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER"
11/12/2008 8-K Form 8-K -- Current report
10/23/2008 8-K Quarterly results
Docs: "OSI Pharmaceuticals Announces Third Quarter 2008 Financial Results — Reports Earnings of $0.56 Per Share From Continuing Operations — — Tarceva Global Net Sales of $279 Million Up 23% Over The Third Quarter of 2007",
"Textual representation of certain portions of the webcast conference call held on October 22, 2008"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy